SCHEMBL3355882

SCHEMBL3355882

C=CC(=O)N1CCCNCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.50
CHKA P35790 1/20 0.50
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA9 Q16790 1/20 0.42
CHRNB2 P17787 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA4 P43681 1/20 0.39
CHRNB3 Q05901 1/20 0.39
CHRNA6 Q15825 1/20 0.39
KMT2A Q03164 3/20 0.36
MEN1 O00255 1/20 0.36
TET3 O43151 2/20 0.36
FBXL19 Q6PCT2 2/20 0.36
CXXC5 Q7LFL8 2/20 0.36
KDM2B Q8NHM5 2/20 0.36
CXXC4 Q9H2H0 2/20 0.36
KDM2A Q9Y2K7 2/20 0.36
TET1 Q8NFU7 1/20 0.36
HRH4 Q9H3N8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18626274 0.96 CA2 (0.43) CA2CHKACA12CA1CA9
SCHEMBL277853 0.92 CA2 (0.48) CA2CHKACA12CA1CA9
Hydrochloric Acid SCHEMBL17397450 0.90 CA2 (0.46) CA2CHKACA12CA1CA9
Formamide SCHEMBL28191106 0.84 CA2 (0.42) CA2CHKACA12CA1CA9
SCHEMBL1591923 0.80
SCHEMBL149678 0.80
SCHEMBL505654 0.80 ALDH1A1 (0.48) KMT2AMEN1TET3FBXL19CXXC5
SCHEMBL2657029 0.80 CA2 (0.50) CA2CHKACA12CA1CA9
Trifluoroacetic Acid SCHEMBL28639089 0.79 PKM (0.43) CA2CHKACA12CA1CA9
Trifluoroacetic Acid SCHEMBL20296564 0.79 PKM (0.43) CA2CHKACA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383884-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. 2024-11-21 US disclosed
CN-112203742-B Membrane containing polymeric ionic liquid for gas separation 国家研究委员会 2023-07-28 CN disclosed
CN-115244089-A Membrane and use thereof 富士胶片制造欧洲有限公司 2022-10-25 CN disclosed
CN-115210270-A Membrane and use thereof 富士胶片制造欧洲有限公司 2022-10-18 CN disclosed
CN-115151580-A Film laminate and use thereof 富士胶片制造欧洲有限公司 2022-10-04 CN disclosed
CN-114599728-A Surface-modified film 富士胶片制造欧洲有限公司 2022-06-07 CN disclosed
CN-107849275-B Ion exchange membrane 富士胶片制造欧洲有限公司 2021-11-02 CN disclosed
CN-112203742-A Membranes containing polymeric ionic liquids for gas separation 国家研究委员会 2021-01-08 CN disclosed
CN-107849274-B Ion exchange membrane 富士胶片制造欧洲有限公司 2020-12-29 CN disclosed
CN-107207878-B Curable composition and film 富士胶片制造欧洲有限公司 2020-08-14 CN disclosed
US-8852640-B2 Micelles for delivery of nitric oxide ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2014-10-07 US disclosed
CN-103717296-A Composite membrane FUJIFILM MFG EUROPE BV 2014-04-09 CN disclosed
WO-2010002450-A2 MICELLES FOR DELIVERY OF NITRIC OXIDE ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) 2010-01-07 WO disclosed
US-20100003338-A1 Micelles for delivery of nitric oxide ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2010-01-07 US disclosed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003338-A1 Micelles for delivery of nitric oxide NOS2, NOS1, NOS3 CA2 893/4885CHKA 485/4885CA12 524/4885
US-20240383884-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE IL2, NFATC1, IL2RA CA2 1859/4885CHKA 298/4885CA12 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.